钇90放射性微球治疗肝脏恶性肿瘤的应用进展  

Application progress of yttrium-90 radiation microspheres in treatment of liver malignancies

作　　者：郑致远(综述) 颜志平(审校) ZHENG Zhi-yuan;YAN Zhi-ping(Department of Interventional Radiology,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Shanghai Institute of Medical Imaging,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院介入治疗科,上海200032 [2]上海市影像医学研究所,上海200032

出　　处：《复旦学报（医学版）》2020年第4期622-627,共6页Fudan University Journal of Medical Sciences

基　　金：国家自然科学基金面上项目(81771948)。

摘　　要：肝脏恶性肿瘤是人体常见的恶性肿瘤之一,其恶性程度较高,由于缺乏有效的系统性治疗方法,中晚期肝脏肿瘤的治疗效果不佳。近些年来,肝脏恶性肿瘤的局部治疗取得了一些明显的进步,钇90放射性栓塞术是一种融合了肿瘤近程放疗和介入治疗的新兴治疗技术。钇90放射性微球治疗肝脏恶性肿瘤具有安全、有效的优势,与传统的经肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)相比,术后患者不良反应率更低、生活质量更好。本文就钇90治疗肝脏恶性肿瘤的原理、优势、适应证和禁忌证方面的最新进展作一综述。Liver malignant tumors are one of the most common malignant tumors in human body,and their malignancy is relatively high.Due to the lack of effective systemic treatment methods,the therapeutic effects of liver tumors in the middle and advanced stages have been poor.In recent years,local treatment of liver malignancies has made some obvious progress.Yttrium-90 radioembolization is an emerging treatment technology that combines short-range radiotherapy and interventional therapy.Yttrium-90 radioactive microspheres have the advantages of safety and effectiveness in the treatment of liver malignancies.Compared with traditional transcatheter arterial chemoembolization(TACE),it has a lower rate of adverse reactions and better quality of life for patients.This article reviews the recent advances in the principles,advantages,indications,and contraindications of yttrium-90 in the treatment of liver malignancies.

关 键 词：钇90微球 介入放射学 放疗栓塞术 肝脏恶性肿瘤 

分 类 号：R815[医药卫生—放射医学]